Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia

Journal of Clinical Oncology

Volumn 31, Issue 34, 2013, Pages 4290-4296

  Aarts, Maureen J ^a   Peters, Frank P ^b   Mandigers, Caroline M ^c   Dercksen, M Wouter ^g   Stouthard, Jacqueline M ⁱ   Nortier, Hans J ^k   Van Laarhoven, Hanneke W ^d   Van Warmerdam, Laurence J ^h   Van De Wouw, Agnes J ^m   Jacobs, Esther M ⁿ   Mattijssen, Vera ^o   Van Der Rijt, Carin C ^j   Smilde, Tineke J ^p   Van Der Velden, Annette W ^q   Temizkan, Mehmet ^r   Batman, Erdogan ^l   Muller, Erik W ^s   Van Gastel, Saskia M ^e   Borm, George F ^d,f   Tjan Heijnen, Vivianne C G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Comprehensive Cancer Centre East ^*  (Netherlands)

^f Nijmegen i   (Netherlands)

^g MÁXIMA MEDICAL CENTER   (Netherlands)

^h CATHARINA HOSPITAL   (Netherlands)

ⁱ Maasstad Medical Center ^*  (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l Diaconessenhuis Leiden   (Netherlands)

^m VIECURI MEDICAL CENTER   (Netherlands)

ⁿ ELKERLIEK HOSPITAL   (Netherlands)

^o RIJNSTATE HOSPITAL   (Netherlands)

^p JEROEN BOSCH HOSPITAL   (Netherlands)

^q MARTINI HOSPITAL   (Netherlands)

^r ST JANSDAL HOSPITAL   (Netherlands)

^s SLINGELAND HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PEGFILGRASTIM; RECOMBINANT PROTEIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER RADIOTHERAPY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DRUG SAFETY; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; AGED; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; TIME; TREATMENT OUTCOME; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892917409     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.6229     Document Type: Article

References (16)

1. Kuderer NM, Dale DC, Crawford JC, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 258-2266, 2006
2. Wildiers H, Reiser M: Relative dose intensity of chemotherapy and its impact on outcome in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77:221-240, 2011
3. Timmer-Bonte JN, de Boo TM, Smit HJ, et al: Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte-colony stimulating factor: A Dutch randomized phase III study. J Clin Oncol 23:7974-7984, 2005 (Pubitemid 46657398)
4. Cullen M, Baijal S: Prevention of febrile neutropenia: Use of prophylactic antibiotics. Br J Cancer 101:S11-S14, 2009 (suppl 1)
5. Aapro MS, Bohlius J, Cameron DA, et al: 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer 47:8-32, 2011
6. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187- 3205, 2006 (Pubitemid 46638957)
7. Timmer-Bonte JN, Adang EM, Smith HJ, et al: Cost-effectiveness of adding granulocyte-colony stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer. J Clin Oncol 24:2991-2997, 2006 (Pubitemid 46638931)
8. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebocontrolled phase III study. J Clin Oncol 23:1178- 1183, 2005
9. Martín M, Lluch A, Seguí M, et al: Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide(TAC)or5-fluorouracil,doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212, 2006 (Pubitemid 44288210)
10. von Minckwitz G, Kümmel S, du Bois A, et al: Pegfilgrastim ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclofosphamide) chemotherapy for breast cancer: Results from the GEPARTIO study. Ann Oncol 19:292-298, 2008 (Pubitemid 351201710)
11. Younis T, Rayson D, Thompson K: Primairy G-CSF prophylaxis for adjuvant TC or FED-D chemotherapy outside of clinical trial settings; a systematic review and meta-analysis. Support Care Cancer 20:2523-2530, 2012
12. Jones SE, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: A 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
13. Burris HA, Belani CP, Kaufman PA, et al: Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non- small-cell lung cancer, ovarian cancer, and non- Hodgkin's lymphoma: Results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6:133-140, 2010
14. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164- 170, 1991
15. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breastcancer. N Engl J Med 352:2302-2313, 2005
16. Shayne M, Culakova E, Poniewierski MS, et al: Dose intensity and hematologic toxicity in older patients receiving systemic chemotherapy. Cancer 110:1611-1620, 2007 (Pubitemid 47463077)